相关实验视频

Updated: Jan 6, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

冠状动脉血管学在患有高脂蛋白的人群中的结果 (a)

Kelvin Supriami^1,2, Christian C Faaborg-Andersen^2,3, So Mi Jemma Cho^2,4,5

¹Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, CPZN 3.187, Boston, MA 02114, USA.

European journal of preventive cardiology

|November 13, 2025

概括

升高的脂蛋白[Lp[a]显著增加了冠状动脉疾病 (CAD) 的风险. 侵袭性冠状动脉血管造影后非常高的Lp (a) 水平与更严重的动脉样硬化和更高的心血管不良事件和死亡率有关.

科学领域:

心脏病学心脏病学
遗传学遗传学是一个
血管生物学血管生物学

背景情况:

升高的脂蛋白 (Lp) 是已知的冠状动脉疾病 (CAD) 的独立风险因素.
侵袭性冠状动脉血管学 (ICA) 后在患有升高Lp (a) 的患者中长期结局数据有限.
了解Lp (a) 对动脉样硬化负担和ICA后临床结果的影响对于风险分层至关重要.

研究的目的:

为了研究Lp (a) 水平和临床结果之间的关联,根据指数ICA.
评估Lp (a) 水平与动脉样硬化斑块负担之间的关系.
识别患有高Lp的个体,他们可能受益于有针对性的降低风险的策略.

主要方法:

在2000年至2023年期间接受ICA的5118名参与者的回顾性分析,使用Lp (a) 测量.
将Lp (a) 水平分为正常,中等,高和非常高.
评估血管学特征,CAD表现和临床结果,包括急性心肌梗塞,再血管化,静脉静脉复缩和死亡率.

主要成果:

19.0%的参与者有非常高的Lp.
非常高的Lp (a) 与严重阻塞性CAD,左主疾病和更高的根西尼分数有关.
在平均随访时间为16.87年,非常高的Lp (a) 与急性心肌梗塞,再血管化,静脉静脉复缩和死亡率的风险增加相关.
在那些接受了旁路手术的人中,非常高的Lp (a) 与随后的皮肤冠状动脉干预的可能性更高有关.

结论:

升高的Lp (a) 与冠状动脉样硬化的更大负担有关.
在患有升高Lp的个体中,ICA后仍然存在显著的不良结果残留风险.
针对患有升高Lp的患者,需要有针对性的降低风险的策略.

关键词:

冠状动脉动脉扫描是一项冠状动脉动脉扫描.根西尼的得分得到了胜利.移植失败是因为移植失败.脂蛋白 (a) 是一种蛋白质结果的结果.重新血管化的治疗方法

更多相关视频

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

相关概念视频

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...